PAVmed Inc.
PAVM- Exchange
- Nasdaq
- Industry
- Surgical & Medical Instruments & Apparatus
- SEC CIK
- 0001624326
No open-market purchases or sales by PAVmed Inc. insiders were filed in the last 90 days; 20 institutions reported holding it in 13F filings for Q2 2026, worth $5.56M in total; no superinvestor holds it.
- Currency
- USD
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Nov 17, 2026, 2:21 AM ET
Income statement
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | – | – | – | – | Mar 29, 2022 |
| Revenue | $71.0K | $3.00M | $2.50M | $377.0K | $500.0K |
| Cost of revenue | $218.0K | $4.84M | $6.42M | $3.61M | $585.0K |
| Gross profit | – | – | – | – | -$85.0K |
| Operating expenses | – | – | – | – | $54.3M |
| Research and development | $4.49M | $5.93M | $14.3M | $25.5M | $19.8M |
| Selling, general and administrative | $16.3M | $24.5M | $30.9M | $41.0M | $25.6M |
| Operating income | -$21.8M | -$44.5M | -$68.8M | -$90.9M | -$54.4M |
| Interest expense | – | $45.0K | $589.0K | $1.27M | – |
| Income tax | $0 | – | – | – | – |
| Net income | $401.0K | $39.8M | -$64.2M | -$89.0M | -$50.3M |
| EPS, basic | $-5.63 | $3.30 | $-9.16 | $-1.00 | – |
| EPS, diluted | $-5.63 | $0.50 | $-9.16 | – | – |
| Weighted shares, basic | 670.5K | 9.67M | 7.23M | 89.1M | – |
| Weighted shares, diluted | 670.5K | 65.3M | 7.23M | – | – |
| Margins and growth | |||||
| Gross margin | – | – | – | – | -17.0% |
| Operating margin | -30712.7% | -1482.9% | -2751.8% | -24118.6% | -10878.6% |
| Net margin | 564.8% | 1326.4% | -2567.0% | -23602.9% | -10069.4% |
| Revenue growth, year over year | −97.6% | +20.0% | +563.1% | −24.6% | – |
| Net income growth, year over year | −99.0% | – | – | – | – |
Balance sheet
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | – | – | – | – | Mar 29, 2022 |
| Cash and equivalents | $1.54M | $1.19M | $19.6M | $39.7M | $77.3M |
| Accounts receivable | $15.0K | $18.0K | $61.0K | $17.0K | $200.0K |
| Inventory | – | – | $278.0K | – | – |
| Total current assets | $2.56M | $2.16M | $24.5M | $43.9M | $82.6M |
| Property, plant and equipment | $77.0K | $151.0K | $1.78M | $2.45M | $1.58M |
| Intangible assets | – | – | $1.42M | $3.44M | $2.03M |
| Total assets | $38.8M | $30.7M | $33.1M | $54.0M | $87.0M |
| Accounts payable | $678.0K | $657.0K | $1.79M | $2.70M | $3.30M |
| Total current liabilities | $14.8M | $35.4M | $54.2M | $41.2M | – |
| Total liabilities | $16.5M | $37.7M | $57.1M | $43.0M | $7.56M |
| Shareholders' equity | $22.3M | -$7.03M | -$24.0M | $10.9M | $79.4M |
Cash flow statement
Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | – | – | – | – | Mar 29, 2022 |
| Operating cash flow | -$5.21M | -$33.6M | -$52.0M | -$71.0M | -$40.6M |
| Capital expenditures | $31.0K | $55.0K | $242.0K | $1.54M | $1.47M |
| Free cash flow | -$5.24M | -$33.6M | -$52.3M | -$72.5M | -$42.1M |
| Depreciation and amortization | $105.0K | $1.20M | $2.93M | $2.46M | – |
| Stock-based compensation | $1.71M | $6.45M | $11.1M | $19.5M | $15.0M |
| Investing cash flow | -$31.0K | -$16.2M | $758.0K | -$4.74M | -$3.72M |
| Financing cash flow | $5.59M | $31.3M | $31.2M | $38.2M | $104.3M |
| Net change in cash | $353.0K | -$18.5M | -$20.1M | -$37.5M | $60.0M |
| Ratio | |||||
| Stock-based compensation, % of revenue | 2404.2% | 215.0% | 445.6% | 5180.9% | 3001.8% |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits. Stock splits since Dec 31, 2020, from 13F share counts: 1-for-15 in Q4 2023 and 1-for-30 in Q1 2026.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.